CL2015000426A1 - Uso del profarmaco ester de etilo del acido n-(3-carboxi-1-oxopropil)-(4s)-p-fenilfenilmetil)-4-amino-(2r)-metilbutanoico o del acido n-(3-carboxi-1-oxopropil)-(4s)-p-fenilfenilmetil)-(2r)-4-amino-metilbutanoico, inhibidores de nep, junto a valsartan, para tratar la insuficiencia cardiaca con fraccion de eyeccion preservada. - Google Patents

Uso del profarmaco ester de etilo del acido n-(3-carboxi-1-oxopropil)-(4s)-p-fenilfenilmetil)-4-amino-(2r)-metilbutanoico o del acido n-(3-carboxi-1-oxopropil)-(4s)-p-fenilfenilmetil)-(2r)-4-amino-metilbutanoico, inhibidores de nep, junto a valsartan, para tratar la insuficiencia cardiaca con fraccion de eyeccion preservada.

Info

Publication number
CL2015000426A1
CL2015000426A1 CL2015000426A CL2015000426A CL2015000426A1 CL 2015000426 A1 CL2015000426 A1 CL 2015000426A1 CL 2015000426 A CL2015000426 A CL 2015000426A CL 2015000426 A CL2015000426 A CL 2015000426A CL 2015000426 A1 CL2015000426 A1 CL 2015000426A1
Authority
CL
Chile
Prior art keywords
phenylphenylmethyl
carboxy
amino
oxopropyl
methylbutanoic
Prior art date
Application number
CL2015000426A
Other languages
English (en)
Spanish (es)
Inventor
Christoph Shumacher
Thomas Holbro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49000959&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015000426(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2015000426A1 publication Critical patent/CL2015000426A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2015000426A 2012-08-24 2015-02-23 Uso del profarmaco ester de etilo del acido n-(3-carboxi-1-oxopropil)-(4s)-p-fenilfenilmetil)-4-amino-(2r)-metilbutanoico o del acido n-(3-carboxi-1-oxopropil)-(4s)-p-fenilfenilmetil)-(2r)-4-amino-metilbutanoico, inhibidores de nep, junto a valsartan, para tratar la insuficiencia cardiaca con fraccion de eyeccion preservada. CL2015000426A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261692911P 2012-08-24 2012-08-24

Publications (1)

Publication Number Publication Date
CL2015000426A1 true CL2015000426A1 (es) 2015-10-02

Family

ID=49000959

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000426A CL2015000426A1 (es) 2012-08-24 2015-02-23 Uso del profarmaco ester de etilo del acido n-(3-carboxi-1-oxopropil)-(4s)-p-fenilfenilmetil)-4-amino-(2r)-metilbutanoico o del acido n-(3-carboxi-1-oxopropil)-(4s)-p-fenilfenilmetil)-(2r)-4-amino-metilbutanoico, inhibidores de nep, junto a valsartan, para tratar la insuficiencia cardiaca con fraccion de eyeccion preservada.

Country Status (26)

Country Link
US (3) US9517226B2 (https=)
EP (2) EP2887961B1 (https=)
JP (4) JP6482462B2 (https=)
KR (2) KR20200111822A (https=)
CN (2) CN104602711A (https=)
AU (1) AU2013304949C1 (https=)
BR (1) BR112015003067A2 (https=)
CA (1) CA2882771C (https=)
CL (1) CL2015000426A1 (https=)
DK (1) DK2887961T3 (https=)
ES (1) ES2879550T3 (https=)
HU (1) HUE054885T2 (https=)
IL (1) IL237114B (https=)
MA (1) MA37850A1 (https=)
MX (1) MX378867B (https=)
NZ (1) NZ704604A (https=)
PH (1) PH12015500375A1 (https=)
PL (1) PL2887961T3 (https=)
PT (1) PT2887961T (https=)
RU (1) RU2667643C2 (https=)
SG (1) SG11201500256UA (https=)
SI (1) SI2887961T1 (https=)
TN (1) TN2015000028A1 (https=)
TW (1) TWI634887B (https=)
WO (1) WO2014029848A1 (https=)
ZA (1) ZA201500262B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
ES2879550T3 (es) 2012-08-24 2021-11-22 Novartis Ag Inhibidores de epn para tratar enfermedades caracterizadas por la dilatación o remodelación auriculares.
DK3038654T3 (da) 2013-08-26 2020-02-03 Novartis Ag Ny anvendelse
EP3110449B1 (en) * 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
WO2015154673A1 (en) * 2014-04-10 2015-10-15 Zhaoyin Wang Novel prodrugs and combinations for treatment of hypertension and cardiovascular diseases
EP2990800A1 (en) * 2014-08-29 2016-03-02 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Neprilysin as heartfailure (HF) prognostic marker
EP4212152B1 (en) * 2015-05-11 2025-04-30 Novartis AG Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure
US20180140579A1 (en) 2015-05-29 2018-05-24 Novartis Ag Sacubitril and valsartan for treating metabolic disease
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
CN105997994A (zh) * 2015-07-11 2016-10-12 凌莉 一种固体口服型制剂及其制备方法
CN105997993B (zh) * 2015-07-11 2018-03-30 麦丽芳 一种用于心血管疾病治疗的固体口服型制剂及其制备方法
EP3355880A1 (en) 2015-08-28 2018-08-08 Novartis AG New use
ES3036922T3 (en) 2016-02-03 2025-09-25 Novartis Ag New use of a combination of sacubitril and valsartan
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
WO2019008485A1 (en) 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
UY38072A (es) * 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
EP3840746A1 (en) 2018-08-23 2021-06-30 Novartis AG New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
BR112021016198A2 (pt) 2019-03-08 2021-11-03 Boehringer Ingelheim Int Formulações de anticorpo anti-il-36r

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3004206A1 (de) 1980-02-06 1981-08-13 Hoechst Ag, 6000 Frankfurt Verfahren zur herstellung von 1-alkyl-1-phenylhydrazinen
DE3005674A1 (de) 1980-02-15 1981-08-20 Ruhr-Zink GmbH, 4354 Datteln Verwendung einer blei-legierung fuer anoden bei der elektrolytischen gewinnung von zink
DE3010374A1 (de) 1980-03-18 1981-10-08 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von copolymerisaten von styrol und/oder dessen derivaten
US4610816A (en) 1980-12-18 1986-09-09 Schering Corporation Substituted dipeptides as inhibitors of enkephalinases
US4383527A (en) 1981-02-20 1983-05-17 Howmedica, Inc. Device for guiding the insertion of surgical wires into bone tissue
EP0063662B1 (fr) 1981-04-24 1986-01-02 Jean Martin Ensemble préfabriqué pour la réalisation d'ossature pour la construction
ZA84670B (en) 1983-01-31 1985-09-25 Merck & Co Inc Thiorphan analogs as enkephalinase and angiotensin converting enzyme inhibitors
US4722810A (en) 1984-08-16 1988-02-02 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
US4929641B1 (en) 1988-05-11 1994-08-30 Schering Corp Mercapto-acylamino acid antihypertensives
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
US4740499A (en) 1986-07-28 1988-04-26 Monsanto Company Method of enhancing the bioactivity of atrial peptides
GB8811873D0 (en) 1988-05-19 1988-06-22 Pfizer Ltd Therapeutic agents
GB2218983A (en) 1988-05-27 1989-11-29 Pfizer Ltd Spiro-substituted glutaramides as diuretics
GB8812597D0 (en) 1988-05-27 1988-06-29 Pfizer Ltd Therapeutic agents
EP0361365A1 (en) 1988-09-30 1990-04-04 E.R. SQUIBB & SONS, INC. Aminobenzoic and aminocyclohexane-carboylic acid compounds, compositions, and their method of use
GB8903740D0 (en) 1989-02-18 1989-04-05 Pfizer Ltd Therapeutic agents
IL97219A (en) 1990-02-19 1995-12-08 Ciba Geigy Ag Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
US5223516A (en) 1990-03-22 1993-06-29 E. R. Squibb & Sons, Inc. 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
US5294632A (en) 1991-05-01 1994-03-15 Ciba-Geigy Corporation Phosphono/biaryl substituted dipetide derivatives
US5250522A (en) 1992-10-09 1993-10-05 Ciba-Geigy Corporation Phosphono/biaryl substituted amino acid derivatives
US5273990A (en) 1992-09-03 1993-12-28 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives
GB9123353D0 (en) 1991-11-04 1991-12-18 Fujisawa Pharmaceutical Co New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
WO1993010773A1 (en) 1991-12-06 1993-06-10 Schering-Plough S.P.A. Use of neutral endopeptidase inhibitors in the treatment of left ventricular hypertrophy
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
DE4233296C1 (de) 1992-10-02 1994-03-31 Heitland Und Petre Int Gmbh Behälter für Kosmetikprodukte
WO1994015908A1 (fr) 1993-01-14 1994-07-21 Yoshitomi Pharmaceutical Industries, Ltd. Derive de propionamide et son utilisation medicinale
JPH06234754A (ja) 1993-02-10 1994-08-23 Dai Ichi Seiyaku Co Ltd 複素環式カルボン酸誘導体
IT1266571B1 (it) 1993-07-30 1997-01-09 Zambon Spa Derivati della beta-mercapto-propanammide utili nel trattamento delle malattie cardiovascolari
JP3576193B2 (ja) 1993-12-03 2004-10-13 第一製薬株式会社 ビフェニルメチル置換バレリルアミド誘導体
US6201002B1 (en) 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
DK1467728T3 (da) * 2002-01-17 2007-12-27 Novartis Ag Farmaceutiske sammensætninger indeholdende valsartan og NEP-inhibitorer
RU2245162C2 (ru) * 2003-01-04 2005-01-27 Козлов Владимир Александрович Способ терапии инфаркта миокарда
US20070054947A1 (en) 2003-05-16 2007-03-08 Cohn Jay N Pharmaceutical composition comprising valsartan
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP3067043B1 (en) * 2007-11-06 2022-11-30 Novartis AG Pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
WO2012027237A1 (en) * 2010-08-24 2012-03-01 Novartis Ag Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy
ES2879550T3 (es) 2012-08-24 2021-11-22 Novartis Ag Inhibidores de epn para tratar enfermedades caracterizadas por la dilatación o remodelación auriculares.

Also Published As

Publication number Publication date
JP6482462B2 (ja) 2019-03-13
RU2667643C2 (ru) 2018-09-21
IL237114A0 (en) 2015-03-31
TN2015000028A1 (en) 2016-06-29
AU2013304949B2 (en) 2016-08-11
ES2879550T3 (es) 2021-11-22
US11135192B2 (en) 2021-10-05
WO2014029848A1 (en) 2014-02-27
JP7407508B2 (ja) 2024-01-04
KR20150046039A (ko) 2015-04-29
BR112015003067A2 (pt) 2017-07-04
AU2013304949A1 (en) 2015-02-05
JP2022020624A (ja) 2022-02-01
US20180200218A1 (en) 2018-07-19
EP3943084A1 (en) 2022-01-26
SI2887961T1 (sl) 2021-08-31
MX378867B (es) 2025-03-11
US20150190376A1 (en) 2015-07-09
EP2887961B1 (en) 2021-04-28
KR102159601B1 (ko) 2020-09-28
HUE054885T2 (hu) 2021-10-28
EP2887961A1 (en) 2015-07-01
MA37850A1 (fr) 2018-07-31
SG11201500256UA (en) 2015-04-29
CN104602711A (zh) 2015-05-06
HK1205930A1 (en) 2015-12-31
US9517226B2 (en) 2016-12-13
DK2887961T3 (da) 2021-07-19
IL237114B (en) 2020-10-29
JP2023159114A (ja) 2023-10-31
KR20200111822A (ko) 2020-09-29
RU2018126749A3 (https=) 2021-12-28
AU2013304949C1 (en) 2020-12-24
JP2015526458A (ja) 2015-09-10
NZ704604A (en) 2018-06-29
PH12015500375A1 (en) 2015-04-20
TWI634887B (zh) 2018-09-11
PL2887961T3 (pl) 2021-11-08
TW201414471A (zh) 2014-04-16
CA2882771A1 (en) 2014-02-27
ZA201500262B (en) 2016-09-28
US20170049738A1 (en) 2017-02-23
RU2018126749A (ru) 2019-03-12
CN108685889A (zh) 2018-10-23
RU2015110240A (ru) 2016-10-20
MX2015002432A (es) 2015-06-22
CA2882771C (en) 2021-02-23
JP2019069954A (ja) 2019-05-09
PT2887961T (pt) 2021-07-28
US9937143B2 (en) 2018-04-10

Similar Documents

Publication Publication Date Title
CL2015000426A1 (es) Uso del profarmaco ester de etilo del acido n-(3-carboxi-1-oxopropil)-(4s)-p-fenilfenilmetil)-4-amino-(2r)-metilbutanoico o del acido n-(3-carboxi-1-oxopropil)-(4s)-p-fenilfenilmetil)-(2r)-4-amino-metilbutanoico, inhibidores de nep, junto a valsartan, para tratar la insuficiencia cardiaca con fraccion de eyeccion preservada.
LT4342546T (lt) Eikozapentaeno rūgšties etilo esteris, skirtas panaudoti mažinant nemirtino insulto riziką subjektams, gydomiems statinais
CL2014001930A1 (es) Formulacion farmacéutica que comprende un anticuerpo angiopoyetina 2 (anti-ang2).
IT1400982B1 (it) Collirio osmotico trans-epiteliale per la cura del cheratocono.
CL2014002757A1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
CL2014000459A1 (es) Compuestos derivados de heterociclos biciclicos con nitrogeno; composicion farmaceutica; uso para tratar la hipertension arterial pulmonar.
MX2015012644A (es) Tratamiento de cataplejia.
BR112015011112A2 (pt) composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença.
EP3799860C0 (en) LYOPHILIZED DRUG NANOSUSPENSIONS
CL2013003129A1 (es) Composicion herbicida de emulsión de aceite en agua, estable de alta resistencia; metodo para preparar dicha composicion.
EP2875005A4 (en) N- (3-HETEROARYLARYL) -4-ARYLARYLCARBOXAMIDE AND ANALOG AS INHIBITORS OF THE HEDGEHOG SIGNAL PATH AND USE THEREOF
CL2013000801A1 (es) Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion
EA201600495A1 (ru) Пролекарство адреномедуллина на основе полиэтиленгликоля и его применение
CL2014003165A1 (es) Proceso mejorado para la preparación de treprostinil y derivados del mismo.
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
DK2667856T3 (da) Medicinsk indretning indeholdende en tørstofsammensætning omfattende aripiprazol som en aktiv ingrediens, og en tørstofsammensætning omfattende aripiprazol som en aktiv ingrediens
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
BR112013022523A2 (pt) uso de glicopirrolato para o tratamento de taquicardia
CL2013000513A1 (es) Uso de una composicion farmaceutica que comprende: a) un compuesto monohidratado formado por dos aniones y un cation o b) valsartan y un etil-ester de acido, para el tratamiento de hipertension y/o la prevencion o el tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante.
BR112015014885A2 (pt) combinação de agentes ativos, composição cosmética e/ou dermatológica e processo para a preparação de uma composição de agentes ativos.
FR3016521B1 (fr) Principe actif obtenu a partir de pichia anomala et utilisation pour lutter contre le phenomene d'inflammation chronique de la peau
CL2013001579A1 (es) Uso de una composicion farmaceutica que comprende un compuesto agonista ep4 para tratar marcas de la piel tales como heridas superficiales, cicatrices o arrugas.
CL2013000831A1 (es) Metodo para la determinacion del contenido de alergenos de una composicion.
CL2015000233A1 (es) Compuestos derivados del acido 5-aminolevulinico (5-ala); composicion que los comprende; y su uso para diagnosticar o tratar cancer, una infeccion asociada al cancer, una infeccion viral, bacteriana o fungica e inflamacion, entre otros.
BR112014026795A2 (pt) composição cosmética , processo cosmético para tratar a matéria queratínica e uso de uma composição cosmética.